Roivant SciencesFRA:87S +6.91%55 PB Ratio is 5.52 as of Jun. 26, 2026, which is 134% above its 10-year median of 2.36. GuruFocus rates FRA:87S with a GF Score™ of 55/100 and a GF Value™ of €8.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,232 Biotechnology companies, Roivant Sciences ranks worse than 73.05% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Roivant Sciences's share price is €30.01. Roivant Sciences's Book Value per Share for the quarter that ended in Mar. 2026 was €5.44. Hence, Roivant Sciences's PB Ratio of today is 5.52.
Warning Sign:
Roivant Sciences Ltd stock PB Ratio (=5.41) is close to 2-year high of 5.41.
The historical rank and industry rank for Roivant Sciences's PB Ratio or its related term are showing as below:
FRA:87S'
s PB Ratio Range Over the Past 10 Years
Min: 1.31 Med: 2.36 Max: 10.61
Current: 5.41
During the past 6 years, Roivant Sciences's highest PB Ratio was 10.61. The lowest was 1.31. And the median was 2.36.
FRA:87S's PB Ratio is ranked worse than 73.05% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:87S: 5.41
During the past 12 months, Roivant Sciences's average Book Value Per Share Growth Rate was -6.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 60.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 29.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Roivant Sciences was 60.40% per year. The lowest was 41.30% per year. And the median was 41.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Roivant Sciences PB Ratio Related Terms
Roivant Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Roivant Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Roivant Sciences (FRA:87S) has a PB Ratio of 5.52 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Roivant Sciences and its competitors. This is 134% above median its historical median of 2.36. Over the past decade, Roivant Sciences' PB Ratio has ranged from 1.31 to 10.61. According to the industry distribution chart, Roivant Sciences ranks #900 out of 1232 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Roivant Sciences' PB Ratio too high?
Roivant Sciences' current PB Ratio of 5.52 is 134% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 10.61. The Biotechnology industry median PB Ratio is 2.80. Roivant Sciences' value of 5.52 is 97.1% above this industry median. Based on the distribution chart, Roivant Sciences ranks #900 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' PB Ratio compare to INSM and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #900 out of 1232 companies for PB Ratio. This places Roivant Sciences in the lower half of its industry. The industry median PB Ratio is 2.80. Roivant Sciences' value of 5.52 is 97.1% above this benchmark. Historically, Roivant Sciences' own PB Ratio has ranged from 1.31 to 10.61 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 2.80, Roivant Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roivant Sciences's current PB Ratio of 5.52 is 97.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Roivant Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current PB Ratio is 5.52, which is 134% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (FRA:87S) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.56, compared to a current price of €30.01 — trading 250.6% above its estimated fair value. The current PB Ratio is 5.52, which is 134% above median its 10-year median of 2.36 and 97.1% above the Biotechnology industry median of 2.80. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Roivant Sciences (FRA:87S), the current PB Ratio is 5.52 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (FRA:87S) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of €30.01 is trading 250.6% above its estimated GF Value™ of €8.56.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for FRA:87S:
PB Ratio: 5.52 (134% above median its 10-year median of 2.36)
GF Value™: €8.56 vs. price of €30.01 (250.6% above fair value)
Industry Position: 97.1% above the Biotechnology median (#900 of 1232)
No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score
Get the complete analysis for FRA:87S
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:87S has been successfully added to your 
